This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Medical management of endometriosis is primarily based on the principle that the endometriotic lesions are responsive to estrogen. Tissue selective estrogen receptor modulators (SERMs) are drugs that act as estrogen agonists on some organs and tissues (e.g., connective tissues, nervous system), but have either no effect or act as estrogen antagonists in others (e.g., reproductive tract, mammary gland). Recently, a new proprietary SERM (ZK 619) was developed that maintained bone density similar to estradiol (E2), but inhibited E2 action on the uterus in rodents. In this study we tested the effects of ZK 619, a SERM, and ZK 211, a pure progesterone antagonist (PA), on ectopic endometrial grafts, an experimental model for endometriosis, in estrogen-treated rhesus macaques.
Showing the most recent 10 out of 492 publications
